STK3 and Chagas disease: Bearing in mind the pharmacokinetic limitations of DMU759 with regard to plasma protein binding and metabolic instability, the efficacy achieved with this compound in vivo suggests that pharmacokinetically optimized analogs from this series or others targeting KRS1 may have potential for effectively treating T. cruzi infection in this acute mouse model of Chagas disease.